SEHK:2162Biotechs
Keymed Biosciences Full Year 2023 Earnings: EPS Misses Expectations
Keymed Biosciences ( HKG:2162 ) Full Year 2023 Results Key Financial Results Revenue: CN¥354.1m (up 254% from FY 2022...
Stock Analysis
Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.